AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00657033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
Study NCT00657033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
Study NCT04563975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab，240mg，d1，Intravenous Infusion，q3w
Study NCT04563975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel，60-75mg/m2，d8 and d15，Intravenous Infusion，q3w
Study NCT04563975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel，125mg/m2，d1 and d 8，Intravenous Infusion，q3w
Study NCT02009397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02009397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Study NCT01253551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence AB
Description: Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Study NCT01253551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment sequence BA
Description: Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Study NCT04528212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Tablets
Description: Glimepiride (4 mg) per Day
Study NCT04528212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride plus fenofibrate
Description: Glimepiride (4 mg) plus Fenofibrate (160 mg) per Day
Study NCT04528212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride plus curcumin
Description: Glimepiride (4 mg) plus Curcumin (1100 mg) With 5mg Black Pepper per Day
Study NCT02315495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Study NCT02315495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Study NCT02000700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: One 100-mg tablet of canagliflozin orally administered daily for 14 days.
Study NCT02000700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: One 50-mg tablet of canagliflozin orally administered daily for 14 days.
Study NCT02000700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: One 300-mg tablet of canagliflozin orally administered daily for 14 days.
Study NCT02000700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One matching placebo tablet orally administered at baseline phase.
Study NCT03743649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01897831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xin te mie
Description: durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
Study NCT01218945 — intervention group
Intervention type: PROCEDURE
Intervention: Cell Culture
Description: Aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. Therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.
Study NCT02952248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Study NCT04960683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat training
Description: Control group will receive the routine conventional physiotherapy treatment and the treatment for this group consists of the following:~Conventional therapy protocol:~* 5 sessions of 45 minutes a week, each session includes:~* 5 minutes of stretching exercise~* 20 minutes of strengthening exercise~* 10 minutes of balance exercise~* 10 minutes of gait training~Experimental group will receive 45 min of Lokomat in addition to the conventional approach (as explained above). Since Lokomat appointments can be only 8 per day, it is planned to have two groups of 8 participants for 4 weeks each. The Lokomat training include the following:~* 5 sessions of 45 minutes of conventional therapy (same as above) per week~* 5 sessions of 45 minutes on Lokomat per week
Study NCT04960683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lokomat training
Description: Control group will receive the routine conventional physiotherapy treatment and the treatment for this group consists of the following:~Conventional therapy protocol:~* 5 sessions of 45 minutes a week, each session includes:~* 5 minutes of stretching exercise~* 20 minutes of strengthening exercise~* 10 minutes of balance exercise~* 10 minutes of gait training~Experimental group will receive 45 min of Lokomat in addition to the conventional approach (as explained above). Since Lokomat appointments can be only 8 per day, it is planned to have two groups of 8 participants for 4 weeks each. The Lokomat training include the following:~* 5 sessions of 45 minutes of conventional therapy (same as above) per week~* 5 sessions of 45 minutes on Lokomat per week
Study NCT01226498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood Cells auto-transfusion
Description: Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
Study NCT04193956 — intervention group
Intervention type: OTHER
Intervention: Standard-of-care procedures
Description: Patients receive standard of care anti-PD-1 treatment as monotherapy or in combination with other checkpoint inhibitors. Related assessments, as laboratory assessments, CT-thorax-abdomen and FDG-PET will be performed according to clinical routine procedures.
Study NCT04431271 — intervention group
Intervention type: PROCEDURE
Intervention: Robot-assisted hernia repair
Description: Inguinal hernia repair was performed using the DaVinci Xi robotic system
Study NCT04193956 — intervention group
Intervention type: OTHER
Intervention: Study procedures
Description: Patients will undergo tumor biopsies, venous blood sampling and feces sampling in combination with a food questionnaire before, during and at the end of standard of care anti-PD-1 treatment.
Study NCT02411422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional endotracheal tube
Description: Conventional endotracheal tube
Study NCT02411422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reinforced endotracheal tube
Description: Reinforced endotracheal tube
Study NCT04226183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pregnancy workout
Description: Procedure of pregnancy workout has been legalized by the Ministry of Health of Indonesia act 2014 No.97.~100 ml fresh guava juice without sugar
Study NCT04614285 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial excavation
Description: Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude.
Study NCT04614285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial excavation
Description: Operators sign up for participation at the homepage of Center for Pediatric Oral Health Research (ABC). The study will be carried out in a Practice-Based Research Network setting. All practitioners interested in participating in the study will get access to an online information about their participation after they signed up. The participation starts by answering a questionnaire on their treatment attitudes and experiences.~Patients will be identified during the routine dental examination. If a carious lesion in the primary molars is detected and in a need of a restoration, the children and parents will be asked to participate in the study.~The parents receive information about the study and give their consent. Allocation into treatment groups will be performed by random assignment by the homepage of ABC.~After the study is finished the participating dentist will be asked to answer the same questionnaire to investigate the effect of the participation on the operators attitude.
Study NCT04015128 — intervention group
Intervention type: DEVICE
Intervention: Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System
Description: The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
Study NCT02801877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare
Study NCT02801877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hub App with the Recommender System
Study NCT03173742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1, T2, T3
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study NCT02801877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Study NCT03173742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1,T3,T2
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study NCT02228174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrauterine Ultrasound-Guided Radiofreq. Ablation System
Description: The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding(HMB).
Study NCT03173742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2,T1,T3
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study NCT02717169 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biometrical tracker
Description: 35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
Study NCT02724371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mentor Larger Size MemoryGel Ultra High Profile Breast Implant
Description: The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
Study NCT01955460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study NCT01955460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01955460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT01955460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01955460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGFR-transduced Autologous T Lymphocytes
Description: Given IV
Study NCT01955460 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Description: Given IV
Study NCT01035528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
Study NCT01035528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
Study NCT02617108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley balloon
Description: a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
Study NCT03065127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g. visuospatial processing, executive function, memory, language, and attention). Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD. Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
Study NCT03065127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD. This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG. During periods of elevated anxiety (e.g. walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
Study NCT03065127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proprioceptive Training
Description: Currently, studies investigating proprioceptive training as a treatment in PD are limited. However, this type of training has potential by improving proprioceptive processing. It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
Study NCT04089683 — intervention group
Intervention type: OTHER
Intervention: Swab stick
Description: Swab sticks collected from Web Spaces, Scrub, Anterior Nares
Study NCT00433381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00433381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT00433381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given orally
Study NCT03173742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2,T3,T1
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study NCT03173742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3,T1,T2
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study NCT03173742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3,T2,T1
Description: T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)
Study NCT00971087 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hologic Selenia Dimensions Digital Breast Tomosynthesis System
Description: Subjects are enrolled from either a screening population or a biopsy population. Both groups are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects recruited in the biopsy population will be imaged on the investigational device prior to their biopsy procedure.
Study NCT02470065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: once daily afatinib at a dose of 40 mg for 8 weeks
Study NCT02470065 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate surgery
Description: anatomical resection and systematic lymph node dissection
Study NCT04155164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive Metformin at 1000mg for 12 months.
Study NCT04155164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo group will take Placebo at 1000mg for 12 months.
Study NCT03445975 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-in-1 perineal care washcloths
Description: The 3-in-1 washcloth was used for daily routine perineal skin hygiene and after each diaper/underpad change. This procedure was intended for cleansing, moisturizing, and application of a barrier protection (dimeticone 3%). 3-in1 washcloths pH range is 3.5 to 5.0.
Study NCT00904020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm
Description: Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
Study NCT00427492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesia
Description: Tablet magnesia 500mg. 2 tablet 2 times a day for a week
Study NCT00427492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00427492 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03256799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor/Ataluren
Description: Both drugs were given in combination for 48 week study period
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 0.3 mg intravenous infusion, C1D1 and afterwards Q2W
Study NCT02470065 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate surgery
Description: anatomical resection and systematic lymph node dissection
Study NCT02408289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lo-Flav
Description: low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 1 mg intravenous infusion, C1D1 and afterwards Q2W
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 3 mg intravenous infusion, C1D1 and afterwards Q2W
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 10 mg intravenous infusion, C1D1 and afterwards Q2W
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 30 mg intravenous infusion, C1D1 and afterwards Q2W
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 100 mg intravenous infusion, C1D1 and afterwards Q2W
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 300 mg intravenous infusion, C1D1 and afterwards Q2W
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: 600 mg intravenous infusion, C1D1 and afterwards Q2W
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: Intravenous infusion, C1D1 and afterwards Q3W
Study NCT02408289 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hi-Flav
Description: High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
Study NCT03875157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: Intravenous infusion Q3W